Global Human Blood Plasma Fractionation 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI06242390

Publication Date:

June 13, 2024

Pages:

131

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Human Blood Plasma Fractionation market size was valued at US$ 29670 million in 2023. With growing demand in downstream market, the Human Blood Plasma Fractionation is forecast to a readjusted size of US$ 50480 million by 2030 with a CAGR of 7.9% during review period.
The research report highlights the growth potential of the global Human Blood Plasma Fractionation market. Human Blood Plasma Fractionation are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Human Blood Plasma Fractionation. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Human Blood Plasma Fractionation market.
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation
The Blood Plasma Fractionation Product market is driven by the growing demand for plasma-derived therapies and the increasing prevalence of chronic and rare diseases. Plasma fractionation involves separating and purifying plasma components to produce therapies such as immunoglobulins, clotting factors, and albumin. The rise in awareness about the therapeutic benefits of plasma-derived products and the need for specialized treatments contribute to market growth as patients and healthcare providers seek effective solutions. Moreover, advancements in fractionation technologies, including improved product yields and safety profiles, align with better patient outcomes. However, the market also faces challenges, including ensuring a stable supply of plasma donors and addressing regulatory complexities related to plasma collection and product manufacturing. Additionally, competition from alternative therapies and addressing concerns about supply chain disruptions can pose obstacles for manufacturers. To succeed, companies must focus on research and development to offer innovative and safe plasma fractionation products, collaborate with healthcare professionals for therapeutic insights, and address the challenges to meet the increasing demand for specialized and life-saving plasma-derived therapies.
Key Features:
The report on Human Blood Plasma Fractionation market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Human Blood Plasma Fractionation market. It may include historical data, market segmentation by Type (e.g., Immune Globulin, Coagulation Factor), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Human Blood Plasma Fractionation market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Human Blood Plasma Fractionation market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Human Blood Plasma Fractionation industry. This include advancements in Human Blood Plasma Fractionation technology, Human Blood Plasma Fractionation new entrants, Human Blood Plasma Fractionation new investment, and other innovations that are shaping the future of Human Blood Plasma Fractionation.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Human Blood Plasma Fractionation market. It includes factors influencing customer ' purchasing decisions, preferences for Human Blood Plasma Fractionation product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Human Blood Plasma Fractionation market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Human Blood Plasma Fractionation market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Human Blood Plasma Fractionation market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Human Blood Plasma Fractionation industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Human Blood Plasma Fractionation market.
麻豆原创 Segmentation:
Human Blood Plasma Fractionation market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Immune Globulin
Coagulation Factor
Albumin
Others
Segmentation by application
Hospital
Retail Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Human Blood Plasma Fractionation 麻豆原创 Size 2019-2030
2.1.2 Human Blood Plasma Fractionation 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Human Blood Plasma Fractionation Segment by Type
2.2.1 Immune Globulin
2.2.2 Coagulation Factor
2.2.3 Albumin
2.2.4 Others
2.3 Human Blood Plasma Fractionation 麻豆原创 Size by Type
2.3.1 Human Blood Plasma Fractionation 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Human Blood Plasma Fractionation 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Human Blood Plasma Fractionation Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Others
2.5 Human Blood Plasma Fractionation 麻豆原创 Size by Application
2.5.1 Human Blood Plasma Fractionation 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Human Blood Plasma Fractionation 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Human Blood Plasma Fractionation 麻豆原创 Size by Player
3.1 Human Blood Plasma Fractionation 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Human Blood Plasma Fractionation Revenue by Players (2019-2024)
3.1.2 Global Human Blood Plasma Fractionation Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Human Blood Plasma Fractionation Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Human Blood Plasma Fractionation by Regions
4.1 Human Blood Plasma Fractionation 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Human Blood Plasma Fractionation 麻豆原创 Size Growth (2019-2024)
4.3 APAC Human Blood Plasma Fractionation 麻豆原创 Size Growth (2019-2024)
4.4 Europe Human Blood Plasma Fractionation 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Human Blood Plasma Fractionation 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Human Blood Plasma Fractionation 麻豆原创 Size by Country (2019-2024)
5.2 Americas Human Blood Plasma Fractionation 麻豆原创 Size by Type (2019-2024)
5.3 Americas Human Blood Plasma Fractionation 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Blood Plasma Fractionation 麻豆原创 Size by Region (2019-2024)
6.2 APAC Human Blood Plasma Fractionation 麻豆原创 Size by Type (2019-2024)
6.3 APAC Human Blood Plasma Fractionation 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Human Blood Plasma Fractionation by Country (2019-2024)
7.2 Europe Human Blood Plasma Fractionation 麻豆原创 Size by Type (2019-2024)
7.3 Europe Human Blood Plasma Fractionation 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Blood Plasma Fractionation by Region (2019-2024)
8.2 Middle East & Africa Human Blood Plasma Fractionation 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Human Blood Plasma Fractionation 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Human Blood Plasma Fractionation 麻豆原创 Forecast
10.1 Global Human Blood Plasma Fractionation Forecast by Regions (2025-2030)
10.1.1 Global Human Blood Plasma Fractionation Forecast by Regions (2025-2030)
10.1.2 Americas Human Blood Plasma Fractionation Forecast
10.1.3 APAC Human Blood Plasma Fractionation Forecast
10.1.4 Europe Human Blood Plasma Fractionation Forecast
10.1.5 Middle East & Africa Human Blood Plasma Fractionation Forecast
10.2 Americas Human Blood Plasma Fractionation Forecast by Country (2025-2030)
10.2.1 United States Human Blood Plasma Fractionation 麻豆原创 Forecast
10.2.2 Canada Human Blood Plasma Fractionation 麻豆原创 Forecast
10.2.3 Mexico Human Blood Plasma Fractionation 麻豆原创 Forecast
10.2.4 Brazil Human Blood Plasma Fractionation 麻豆原创 Forecast
10.3 APAC Human Blood Plasma Fractionation Forecast by Region (2025-2030)
10.3.1 China Human Blood Plasma Fractionation 麻豆原创 Forecast
10.3.2 Japan Human Blood Plasma Fractionation 麻豆原创 Forecast
10.3.3 Korea Human Blood Plasma Fractionation 麻豆原创 Forecast
10.3.4 Southeast Asia Human Blood Plasma Fractionation 麻豆原创 Forecast
10.3.5 India Human Blood Plasma Fractionation 麻豆原创 Forecast
10.3.6 Australia Human Blood Plasma Fractionation 麻豆原创 Forecast
10.4 Europe Human Blood Plasma Fractionation Forecast by Country (2025-2030)
10.4.1 Germany Human Blood Plasma Fractionation 麻豆原创 Forecast
10.4.2 France Human Blood Plasma Fractionation 麻豆原创 Forecast
10.4.3 UK Human Blood Plasma Fractionation 麻豆原创 Forecast
10.4.4 Italy Human Blood Plasma Fractionation 麻豆原创 Forecast
10.4.5 Russia Human Blood Plasma Fractionation 麻豆原创 Forecast
10.5 Middle East & Africa Human Blood Plasma Fractionation Forecast by Region (2025-2030)
10.5.1 Egypt Human Blood Plasma Fractionation 麻豆原创 Forecast
10.5.2 South Africa Human Blood Plasma Fractionation 麻豆原创 Forecast
10.5.3 Israel Human Blood Plasma Fractionation 麻豆原创 Forecast
10.5.4 Turkey Human Blood Plasma Fractionation 麻豆原创 Forecast
10.5.5 GCC Countries Human Blood Plasma Fractionation 麻豆原创 Forecast
10.6 Global Human Blood Plasma Fractionation Forecast by Type (2025-2030)
10.7 Global Human Blood Plasma Fractionation Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Takeda
11.1.1 Takeda Company Information
11.1.2 Takeda Human Blood Plasma Fractionation Product Offered
11.1.3 Takeda Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Takeda Main Business Overview
11.1.5 Takeda Latest Developments
11.2 CSL
11.2.1 CSL Company Information
11.2.2 CSL Human Blood Plasma Fractionation Product Offered
11.2.3 CSL Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 CSL Main Business Overview
11.2.5 CSL Latest Developments
11.3 Grifols
11.3.1 Grifols Company Information
11.3.2 Grifols Human Blood Plasma Fractionation Product Offered
11.3.3 Grifols Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Grifols Main Business Overview
11.3.5 Grifols Latest Developments
11.4 Octapharma
11.4.1 Octapharma Company Information
11.4.2 Octapharma Human Blood Plasma Fractionation Product Offered
11.4.3 Octapharma Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Octapharma Main Business Overview
11.4.5 Octapharma Latest Developments
11.5 Kedrion
11.5.1 Kedrion Company Information
11.5.2 Kedrion Human Blood Plasma Fractionation Product Offered
11.5.3 Kedrion Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Kedrion Main Business Overview
11.5.5 Kedrion Latest Developments
11.6 LFB Group
11.6.1 LFB Group Company Information
11.6.2 LFB Group Human Blood Plasma Fractionation Product Offered
11.6.3 LFB Group Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 LFB Group Main Business Overview
11.6.5 LFB Group Latest Developments
11.7 Biotest
11.7.1 Biotest Company Information
11.7.2 Biotest Human Blood Plasma Fractionation Product Offered
11.7.3 Biotest Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Biotest Main Business Overview
11.7.5 Biotest Latest Developments
11.8 BPL
11.8.1 BPL Company Information
11.8.2 BPL Human Blood Plasma Fractionation Product Offered
11.8.3 BPL Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 BPL Main Business Overview
11.8.5 BPL Latest Developments
11.9 RAAS
11.9.1 RAAS Company Information
11.9.2 RAAS Human Blood Plasma Fractionation Product Offered
11.9.3 RAAS Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 RAAS Main Business Overview
11.9.5 RAAS Latest Developments
11.10 CBPO
11.10.1 CBPO Company Information
11.10.2 CBPO Human Blood Plasma Fractionation Product Offered
11.10.3 CBPO Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 CBPO Main Business Overview
11.10.5 CBPO Latest Developments
11.11 Hualan Bio
11.11.1 Hualan Bio Company Information
11.11.2 Hualan Bio Human Blood Plasma Fractionation Product Offered
11.11.3 Hualan Bio Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Hualan Bio Main Business Overview
11.11.5 Hualan Bio Latest Developments
11.12 Tiantan Bio
11.12.1 Tiantan Bio Company Information
11.12.2 Tiantan Bio Human Blood Plasma Fractionation Product Offered
11.12.3 Tiantan Bio Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Tiantan Bio Main Business Overview
11.12.5 Tiantan Bio Latest Developments
11.13 Shuanglin Bio
11.13.1 Shuanglin Bio Company Information
11.13.2 Shuanglin Bio Human Blood Plasma Fractionation Product Offered
11.13.3 Shuanglin Bio Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Shuanglin Bio Main Business Overview
11.13.5 Shuanglin Bio Latest Developments
11.14 Boya Bio
11.14.1 Boya Bio Company Information
11.14.2 Boya Bio Human Blood Plasma Fractionation Product Offered
11.14.3 Boya Bio Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Boya Bio Main Business Overview
11.14.5 Boya Bio Latest Developments
11.15 Yuanda Shuyang
11.15.1 Yuanda Shuyang Company Information
11.15.2 Yuanda Shuyang Human Blood Plasma Fractionation Product Offered
11.15.3 Yuanda Shuyang Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Yuanda Shuyang Main Business Overview
11.15.5 Yuanda Shuyang Latest Developments
11.16 Weiguang Bio
11.16.1 Weiguang Bio Company Information
11.16.2 Weiguang Bio Human Blood Plasma Fractionation Product Offered
11.16.3 Weiguang Bio Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Weiguang Bio Main Business Overview
11.16.5 Weiguang Bio Latest Developments
11.17 Nanyue Bio
11.17.1 Nanyue Bio Company Information
11.17.2 Nanyue Bio Human Blood Plasma Fractionation Product Offered
11.17.3 Nanyue Bio Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Nanyue Bio Main Business Overview
11.17.5 Nanyue Bio Latest Developments
11.18 KM Biologics
11.18.1 KM Biologics Company Information
11.18.2 KM Biologics Human Blood Plasma Fractionation Product Offered
11.18.3 KM Biologics Human Blood Plasma Fractionation Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 KM Biologics Main Business Overview
11.18.5 KM Biologics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.